The first cardiovascular study of NNMT enzyme inhibition in a heart failure with preserved ejection fraction (HFpEF) mouse model demonstrated that treatment markedly reduced 1-MNA (by 77.1%), 2PY (by 66.2%), and 4PY (by 71.1%) in cardiac tissue, while improving cardiac function, enhancing global longitudinal strain, reversing peak longitudinal strain rate, and significantly reducing left ventricular hypertrophy and fibrosis
Second, emerging research suggests BPC-157 has direct neuroprotective properties that could shield the nerve from inflammatory damage
Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimers diseases
Non-negotiable daily step
Nitric oxide synthase uncoupling: a therapeutic target in cardiovascular diseases
any other use is strictly prohibited by law